Gut Microbiota Predicts Treatment Response to Empagliflozin Among MASLD Patients Without Diabetes MellitusOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study investigated whether baseline gut microbiota composition could predict treatment response to the pharmacological agent empagliflozin in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who did not have diabetes mellitus. Researchers prospectively followed these patients from baseline through week 52 (end of treatment), performing clinical, anthropometric, and laboratory assessments alongside MRI-proton density fat fraction (MRI-PDFF) imaging to track liver fat content. Baseline stool samples underwent shotgun DNA metagenomic sequencing to profile the gut microbiome. Treatment response was defined as an MRI-PDFF decline of 30% or more from baseline to end of treatment.
Who was studied?
The cohort consisted of 45 non-diabetic MASLD patients who used empagliflozin, with a median age of 56.9 years (interquartile range 51.0 to 63.2) and 23 patients (51.1%) male. Of these 45 patients, 22 (48.9%) achieved treatment response by the end of treatment. This was a prospectively followed clinical cohort rather than a public dataset, with baseline stool samples collected from each participant for metagenomic analysis.
What were the most important findings?
Baseline gut microbiome composition differed significantly between patients based on later treatment outcomes, with differences observed in alpha diversity (Shannon index p < 0.001, Simpson index p = 0.001) and beta diversity (p = 0.048). Linear discriminant analysis (LDA) effect size methods were used to identify putative bacterial species associated with treatment response. Multivariable logistic regression was then applied to derive adjusted odds ratios linking specific bacterial species to treatment outcome after accounting for clinical factors. The abstract provided does not name specific taxa such as Faecalibacterium prausnitzii or mention butyrate.
What are the greatest implications of this study?
These findings suggest that baseline gut microbiota diversity and composition may serve as a biomarker to predict which non-diabetic MASLD patients are more likely to respond to empagliflozin therapy. This could support a more personalized approach to selecting pharmacological treatment for MASLD based on an individual's microbiome profile. Further validation would be needed to confirm which specific bacterial species drive this predictive relationship and how they might inform clinical decision-making.